🚀 VC round data is live in beta, check it out!
Marker Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Marker Therapeutics and similar public comparables like BioXcel Therapeutics, Marinomed Biotech, Intervacc, Elicera Therapeutics and more.
Marker Therapeutics Overview
About Marker Therapeutics
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Founded
1992
HQ
Employees
5
Website
Sectors
Financials (LTM)
EV
$13M
Marker Therapeutics Financials
Marker Therapeutics reported last 12-month revenue of $3M and negative EBITDA of ($14M).
In the same LTM period, Marker Therapeutics generated $3M in gross profit, ($14M) in EBITDA losses, and had net loss of ($14M).
Revenue (LTM)
Marker Therapeutics P&L
In the most recent fiscal year, Marker Therapeutics reported revenue of $4M and EBITDA of ($12M).
Marker Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | $4M | XXX | XXX | XXX |
| Gross Profit | $3M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($14M) | XXX | ($12M) | XXX | XXX | XXX |
| EBITDA Margin | (407%) | XXX | (351%) | XXX | XXX | XXX |
| EBIT Margin | (448%) | XXX | (351%) | XXX | XXX | XXX |
| Net Profit | ($14M) | XXX | ($12M) | XXX | XXX | XXX |
| Net Margin | (428%) | XXX | (343%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Marker Therapeutics Stock Performance
Marker Therapeutics has current market cap of $29M, and enterprise value of $13M.
Market Cap Evolution
Marker Therapeutics' stock price is $1.75.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $29M | 18.2% | XXX | XXX | XXX | $-0.73 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMarker Therapeutics Valuation Multiples
Marker Therapeutics trades at 4.0x EV/Revenue multiple, and (1.0x) EV/EBITDA.
EV / Revenue (LTM)
Marker Therapeutics Financial Valuation Multiples
As of April 11, 2026, Marker Therapeutics has market cap of $29M and EV of $13M.
Equity research analysts estimate Marker Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Marker Therapeutics has a P/E ratio of (2.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $29M | XXX | $29M | XXX | XXX | XXX |
| EV (current) | $13M | XXX | $13M | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | (1.0x) | XXX | (1.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.9x) | XXX | (1.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | — | XXX | XXX | XXX |
| P/E | (2.1x) | XXX | (2.4x) | XXX | XXX | XXX |
| EV/FCF | (1.1x) | XXX | (1.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Marker Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Marker Therapeutics Margins & Growth Rates
Marker Therapeutics' revenue in the last 12 month grew by 125%.
Marker Therapeutics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $2.5M for the same period.
Marker Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 125% | XXX | (24%) | XXX | XXX | XXX |
| EBITDA Margin | (407%) | XXX | (351%) | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 137% | XXX | 130% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 422% | XXX | 359% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 351% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Marker Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioXcel Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Marinomed Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Intervacc | XXX | XXX | XXX | XXX | XXX | XXX |
| Elicera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cue Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Marker Therapeutics M&A Activity
Marker Therapeutics acquired XXX companies to date.
Last acquisition by Marker Therapeutics was on XXXXXXXX, XXXXX. Marker Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Marker Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMarker Therapeutics Investment Activity
Marker Therapeutics invested in XXX companies to date.
Marker Therapeutics made its latest investment on XXXXXXXX, XXXXX. Marker Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Marker Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Marker Therapeutics
| When was Marker Therapeutics founded? | Marker Therapeutics was founded in 1992. |
| Where is Marker Therapeutics headquartered? | Marker Therapeutics is headquartered in United States. |
| How many employees does Marker Therapeutics have? | As of today, Marker Therapeutics has over 5 employees. |
| Who is the CEO of Marker Therapeutics? | Marker Therapeutics' CEO is Juan Vera. |
| Is Marker Therapeutics publicly listed? | Yes, Marker Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Marker Therapeutics? | Marker Therapeutics trades under MRKR ticker. |
| When did Marker Therapeutics go public? | Marker Therapeutics went public in 1998. |
| Who are competitors of Marker Therapeutics? | Marker Therapeutics main competitors are BioXcel Therapeutics, Marinomed Biotech, Intervacc, Elicera Therapeutics. |
| What is the current market cap of Marker Therapeutics? | Marker Therapeutics' current market cap is $29M. |
| What is the current revenue of Marker Therapeutics? | Marker Therapeutics' last 12 months revenue is $3M. |
| What is the current revenue growth of Marker Therapeutics? | Marker Therapeutics revenue growth (NTM/LTM) is 125%. |
| What is the current EV/Revenue multiple of Marker Therapeutics? | Current revenue multiple of Marker Therapeutics is 4.0x. |
| Is Marker Therapeutics profitable? | No, Marker Therapeutics is not profitable. |
| What is the current EBITDA of Marker Therapeutics? | Marker Therapeutics has negative EBITDA and is not profitable. |
| What is Marker Therapeutics' EBITDA margin? | Marker Therapeutics' last 12 months EBITDA margin is (407%). |
| What is the current EV/EBITDA multiple of Marker Therapeutics? | Current EBITDA multiple of Marker Therapeutics is (1.0x). |
| What is the current FCF of Marker Therapeutics? | Marker Therapeutics' last 12 months FCF is ($12M). |
| What is Marker Therapeutics' FCF margin? | Marker Therapeutics' last 12 months FCF margin is (347%). |
| What is the current EV/FCF multiple of Marker Therapeutics? | Current FCF multiple of Marker Therapeutics is (1.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.